Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

1.51
Delayed Data
As of Feb 17
 -0.05 / -3.21%
Today’s Change
1.16
Today|||52-Week Range
8.49
+19.84%
Year-to-Date
Sage Therapeutics Leads Biotech Movers on Takeout Rumor
Feb 17 / TheStreet.com - Paid Partner Content
Better Buy: Novavax, Inc. vs. Inovio Pharmaceuticals
Feb 16 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close1.56
Today’s open1.55
Day’s range1.49 - 1.56
Volume7,637,019
Average volume (3 months)7,809,810
Market cap$409.6M
Dividend yield--
Data as of 3:59pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-74.58%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book1.39

Competitors

 Today’s
change
Today’s
% change
NSTGNanoString Technolog...+0.04+0.21%
RXDXIgnyta Inc+0.05+0.52%
XBITXBiotech Inc+0.24+2.00%
AGENAgenus Inc+0.28+6.62%
Data as of 3:59pm ET, 02/17/2017

Financials

Next reporting dateMarch 13, 2017
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Chief Financial Officer, Treasurer &
Senior VP
Barclay A. Phillips
Corporate headquarters
Gaithersburg, Maryland

Forecasts


Search for Jobs